4 Undervalued Biotechnology & Medical Research Stocks for Friday, August 09
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Friday, August 09 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jack Gilleland
Jenna Brashear
Eunice Kim
Grace Malone
| Share Statistics | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16.7 | $202.9 | 10% |
|
| Shares Out (Mil) | 33.4 | 55.4 | 39% |
|
| Institutional Ownership | 96.4% | 92.9% | 69% |
|
| Float (Mil) | 23.1 | 40.7 | 31% |
|
| Beta | na | 1.04 | na |
|
| Avg Daily Volume (000s) | 2,968 | 566 | 85% |
|
| Price Change (52-week) |
(28.9%) | 41.0% | 31% |
|
| Growth | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.3%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 45.6% | (15.7%) | 92% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.250) | ($0.760) | ($0.460) | |
| Month Ago EPS | ($0.250) | ($0.760) | ($0.460) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.250) | ($0.760) | ($0.460) | |
| Year/Year Chg | 25.0% | (73.8%) | (81.1%) | |
| Financials | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($25) | ($44) | 22% |
|
| EPS (TTM) | ($0.967) | ($1.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | ($34) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | ($1) | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($24) | $144 | 1% |
|
| Valuation | KTTA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.38 | 1.97 | 8% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | KTTA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (82.6%) | (47.4%) | 7% |
|
| ROE | (88.8%) | (53.5%) | 10% |
|
| Liabilities to Assets | 5.9% | 29.7% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
Pasithea Therapeutics Corp. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors